Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Zscaler Inc trades at $139.99 (market cap $22.52B). The key difference: Zscaler Inc is far larger — about 27.3× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | ZS | |
|---|---|---|
Market Cap | $826.08M | $22.52B |
Sector | Health | Technology |
52-Week High | $30.81 | $336.27 |
52-Week Low | $16.87 | $118.05 |
Enterprise Value | $1.22B | $20.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Zscaler (ZS) trades at $139.27, down 5.34% on the day, amid mixed signals. The stock shows strong revenue growth with 2025 revenue reaching $2.67 billion and consistent quarterly EPS beats, but remains unprofitable with a net income margin of -2.44%. Technical indicators are bullish on moving averages but show overbought RSI levels. Recent news highlights class action investigations and AI infrastructure cost pressures, yet analyst sentiment remains overwhelmingly positive with a consensus price target of $192.64.
The outlook for ZS is cautiously optimistic driven by robust cybersecurity demand and AI security traction, but risks include profitability challenges, rising costs, and legal scrutiny. Wall Street maintains a strong buy consensus (79% buy ratings), suggesting significant upside potential if execution improves and margins stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
